TREM2 and neoplasm: Triggering receptor expressed on myeloid cells 2 (TREM2) has emerged as a key immunosuppressive target on tumour-associated macrophages (TAMs), where it coordinates protumorigenic and anti-inflammatory functions within the tumour microenvironment (TME).